SIEDY Scale 3, a New Instrument to Detect Psychological Component in Subjects with Erectile Dysfunction

Corona, Giovanni; Ricca, Valdo; Bandini, Elisa; Rastrelli, Giulia; Casale, Helen; Jannini, Emmanuele A.; Sforza, Alessandra; Forti, Gianni; Mannucci, Edoardo; Maggi, Mario

doi:10.1111/j.1743-6109.2012.02762.x

Cited by 72 publications

(92 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[48][49][50][51][52][53][54][55] ED may arise from an alteration of any of these components (precipitating event), but, eventually, it will involve all the others in a redundant way, having negative effects on quality of life, interpersonal relationships, and mood. [51][52][53][54] This complex, multidimensional, interactive model of ED pathogenesis captures the ever-changing, mutual influences of biology, marital and psychological life, and their contributions to the disturbance.…”

Section: Expert Opinionmentioning

confidence: 99%

The safety and efficacy of Avanafil, a new 2^ndgeneration PDE5i: comprehensive review and meta-analysis

Corona

Rastrelli

Burri

et al. 2016

Expert Opinion on Drug Safety

Self Cite

View full text Add to dashboard Cite

Areas covered: All placebo-controlled randomized clinical trials (RCTs) on the effect of avanafil in patients with ED were reviewed and meta-analyzed. So far, 5 different RCTs on avanafil have been published, including 1379 and 605 patients in active and placebo groups, respectively. Avanafil was up to 3-fold superior to placebo in determining successful sexual intercourse. Although head-to-head comparative studies are still lacking, re-analyses of available data, showed that avanafil had comparable efficacy, but lower incidence of drug-related side effects, compared to first-generation PDE5is. Expert opinion: Avanafil specific and peculiar pharmacological profile, addresses several problems that have been documented with first-generation PDE5is. Avanafil should theoretically guarantee a low dropout incidence by ensuring a natural profile of action and a low incidence of side effects. Longer studies and head-to-heard trials are advisable to clarify these issues. ARTICLE HISTORY

show abstract

Section: Expert Opinionmentioning

confidence: 99%

The safety and efficacy of Avanafil, a new 2^ndgeneration PDE5i: comprehensive review and meta-analysis

Corona

Rastrelli

Burri

et al. 2016

Expert Opinion on Drug Safety

Self Cite

View full text Add to dashboard Cite

show abstract

“…This adds to the many other psychological factors in the pathogenesis and maintenance of various sexual dysfunctions in men and women. [41][42][43] The lack of a secure base during childhood may be a negative predictive element for relational and couple life as well as for sexual function. Self-esteem and security in personal relationships could prevent the onset of sexual problems such as ED in men and vaginismus, anorgasmia or dyspareunia in women.…”

Section: Discussionmentioning

confidence: 99%

Attachment styles and sexual dysfunctions: a case–control study of female and male sexuality

et al. 2014

View full text Add to dashboard Cite

The aim of this study was to investigate attachment styles in a group of women and men with sexual dysfunction. We recruited 44 subjects (21 women and 23 men) with sexual dysfunction and 41 subjects (21 women and 20 men) with healthy sexual function as the control group. Validated instruments for the evaluation of male and female sexual dysfunctions (M/F SD) and a psychometric tool specifically designed to investigate attachment style were administered. In women, significant differences were found between subjects with sexual dysfunction and healthy controls. The scales indicating an insecure attachment showed: discomfort with closeness (FSD = 42.85 ± 11.55 vs CTRL = 37.38 ± 8.54; P < 0.01), relationship as secondary (FSD = 26.76 ± 2.60 vs CTRL = 18.42 ± 7.99; P < 0.01), and need for approval (FSD=26.38 ± 3.61 vs CTRL = 20.76 ± 7.36; P < 0.01). Healthy women also had significantly higher scores in secure attachment (confidence: FSD = 24.57 ± 3.89 vs CTRL = 33.42 ± 5.74; P < 0.01). Men with sexual dysfunctions differed from healthy men in confidence (MSD = 30 ± 6.33 vs CTRL = 36.05 ± 5.26; P < 0.01) and in discomfort with closeness (MSD = 39.08 ± 8 vs CTRL = 34.25 ± 7.54; P < 0.05). These results suggest that particular aspects related to insecure attachment have a determinant role in people with sexual dysfunctions. It is therefore fundamental to identify the attachment styles and relational patterns in patients receiving counselling and psychological treatments focussed on sexual problems.

show abstract

“…Data on ED were collected using the Structured Interview on Erectile Dysfunction (SIEDY)45 and its appendix A, which scores ED severity 46. Data on the short version of the International Index of Erectile Function (IIEF-5)47 were available for a subset of almost 600 individuals, the characteristics of which do not differ from the rest of the sample (not shown; see also ref.…”

Section: Visceral Obesity Ed and Low Testosterone Are Comorbidmentioning

confidence: 99%

Erectile dysfunction and central obesity: an Italian perspective

et al. 2014

Self Cite

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a frequent complication of obesity. The aim of this review is to critically analyze the framework of obesity and ED, dissecting the connections between the two pathological entities. Current clinical evidence shows that obesity, and in particular central obesity, is associated with both arteriogenic ED and reduced testosterone (T) levels. It is conceivable that obesity-associated hypogonadism and increased cardiovascular risk might partially justify the higher prevalence of ED in overweight and obese individuals. Conversely, the psychological disturbances related to obesity do not seem to play a major role in the pathogenesis of obesity-related ED. However, both clinical and preclinical data show that the association between ED and visceral fat accumulation is independent from known obesity-associated comorbidities. Therefore, how visceral fat could impair penile microcirculation still remains unknown. This point is particularly relevant since central obesity in ED subjects categorizes individuals at high cardiovascular risk, especially in the youngest ones. The presence of ED in obese subjects might help healthcare professionals in convincing them to initiate a virtuous cycle, where the correction of sexual dysfunction will be the reward for improved lifestyle behavior. Unsatisfying sexual activity represents a meaningful, straightforward motivation for consulting healthcare professionals, who, in turn, should take advantage of the opportunity to encourage obese patients to treat, besides ED, the underlying unfavorable conditions, thus not only restoring erectile function, but also overall health.

show abstract

SIEDY Scale 3, a New Instrument to Detect Psychological Component in Subjects with Erectile Dysfunction

Cited by 72 publications

References 56 publications

The safety and efficacy of Avanafil, a new 2^ndgeneration PDE5i: comprehensive review and meta-analysis

The safety and efficacy of Avanafil, a new 2^ndgeneration PDE5i: comprehensive review and meta-analysis

Attachment styles and sexual dysfunctions: a case–control study of female and male sexuality

Erectile dysfunction and central obesity: an Italian perspective

Contact Info

Product

Resources

About

SIEDY Scale 3, a New Instrument to Detect Psychological Component in Subjects with Erectile Dysfunction

Cited by 72 publications

References 56 publications

The safety and efficacy of Avanafil, a new 2ndgeneration PDE5i: comprehensive review and meta-analysis

The safety and efficacy of Avanafil, a new 2ndgeneration PDE5i: comprehensive review and meta-analysis

Attachment styles and sexual dysfunctions: a case–control study of female and male sexuality

Erectile dysfunction and central obesity: an Italian perspective

Contact Info

Product

Resources

About

The safety and efficacy of Avanafil, a new 2^ndgeneration PDE5i: comprehensive review and meta-analysis

The safety and efficacy of Avanafil, a new 2^ndgeneration PDE5i: comprehensive review and meta-analysis